LGC SeraCare has released the AccuSet™ SARSCoV-2 Performance Panel (material #0820-0410), intended for use by clinical laboratories and diagnostic manufacturers alike, to evaluate SARS-CoV-2 antibody assays.
MILFORD, Massachusetts, June 18, 2020 – LGC SeraCare has released the AccuSet™ SARSCoV-2 Performance Panel (material #0820-0410), intended for use by clinical laboratories and diagnostic manufacturers alike, to evaluate SARS-CoV-2 antibody assays. This eleven-member validation panel contains highly characterized, true patient specimens, offering an out-of-the-box solution to provide confidence, mitigate sourcing challenges and accelerate antibody assay development, validation, verification and onboarding.
Comprised of undiluted, naturally occurring human plasma samples, this panel demonstrates a range of SARS-CoV-2 antibody reactivity. Ten panel members represent collections from multiple individuals positive for antibodies to SARS-CoV-2; a single negative member is also included. A comprehensive data sheet, generated using commercially available SARS-CoV-2 antibody assays, is provided for comparative analysis.
Michael Sweatt, Executive Vice President, LGC SeraCare, stated, “Whether generating validation data for a regulatory submission, or performing assay verification in a clinical laboratory setting, LGC SeraCare’s panel products offer a comprehensive solution to rigorously evaluate your assay. Our suite of products will allow you to confidently develop, challenge, troubleshoot, verify, and validate your assay from initial proof of concept through production and onboarding into the clinical laboratory.”
www.lgcgroup.com www.seracare.com
Notes for editors About LGC
LGC is an international leader in the extended life sciences sector, including human healthcare, agri-food & the environment. LGC provides a comprehensive range of reference materials, proficiency testing schemes, and genomics reagents, as well as research and measurement services. Its scientific tools and solutions enable organizations to advance research, develop new products and form an essential part of their quality and compliance procedures. LGC’s 3,150 employees include internationally recognized scientists who are experts in their field. Headquartered in London, it operates out of 19 countries worldwide and is extensively accredited to quality standards such as GMP, GLP, ISO 13485, ISO 17034, ISO 17043, ISO/IEC 17025 and ISO 9001.
About LGC Clinical Diagnostics
LGC’s Clinical Diagnostic Business Unit exists within the LGC’s Standards Division and is comprised of two operating entities - SeraCare Life Sciences and Maine Standards Company. We are in vitro diagnostic (IVD) manufacturers of clinical diagnostic quality solutions to the extended life science industry.
Our 225+ employees operate FDA-registered and ISO 13485-accredited facilities in Maine, Massachusetts and Maryland and support diagnostic professionals in laboratories across the globe. We partner with IVD developers, pharmaceutical, CRO and academic institutions to share our expertise and resources in clinical chemistry, immunochemistry, serology, molecular diagnostics and clinical genomics.
We are committed to improving patient healthcare by offering products and services that support accurate and reliable diagnostic results.
Media contact
Julian Quigley
Media Relations Manager
LGC
Julian.quigley@lgcgroup.com
+44 (0) 20 8943 8491
For product information, please contact
Eric Morreale
Director of Marketing LGC SeraCare emorreale@seracare.com
+ 1 508-244-6455
